Keynote: M&A in 2026: The Year Pharma Deals Change the Game

Session details:

• Why 2026 is a turning point for pharma M&A: Converging pressures from pipeline gaps, regulatory shifts, and investor expectations are accelerating deal activity.
• What’s driving deal momentum: Capital market readiness, breakthrough modalities, and a backlog of strategic assets coming back to market.
• Where deals are likely to happen: Therapeutic areas and technologies most likely to trigger large-cap, mid-cap, and biotech transactions.
• How valuation and risk frameworks are evolving: What buyers and investors are prioritizing—and discounting—in 2026 deal structures.
• What will separate winners from laggards: The role of timing, decisiveness, and portfolio strategy in a faster, more competitive M&A environment.